FLT3 and acute myeloid leukemia: Two independent phase I/II clinical trials at MDACC are investigating the safety and efficacy of the triplet combination of HMA + venetoclax + FLT3-TKIs for patients with FLT3-mutant R/R or ND AML unfit for chemotherapy (NCT03661307, NCT04140487).